PUMA BIOTECHNOLOGY, INC.

PBYI · XNAS

CIK 1401667fmd_0E1RV1AJ54E24SWWCTQXZANRZGManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2008 to Sep 30, 2026, 68 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	–	28	251	272	225	253	228	236	230	228
Cost of revenue	–	6	35	37	39	64	55	63	64	58
Gross profit	–	22	216	235	186	189	173	173	166	170
Research and development	223	208	165	133	98	72	52	50	55	62
Selling, general and administrative	54	107	146	142	118	116	90	90	80	71
Total operating expenses	277	320	346	311	256	–	–	–	–	–
Operating income	(277)	(292)	(95)	(39)	(30)	1	24	33	31	37
Interest expense	–	1	11	15	14	13	12	13	12	7
Interest and investment income	1	1	2	3	0	0	1	3	5	4
Other non-operating income (expense)	1	0	(19)	(36)	(29)	(30)	(23)	(10)	(7)	(2)
Income before taxes	–	–	(114)	(76)	(60)	(29)	0	23	24	36
Income tax expense	0	0	0	0	0	0	0	1	(6)	5
Net income from continuing operations	–	–	(114)	(76)	(60)	(29)	0	22	30	31
Net income	(276)	(292)	(114)	(76)	(60)	(29)	0	22	30	31
Net income to common shareholders	(276)	(292)	(114)	(76)	(60)	–	–	–	–	–